About

Lit Search

Find our February Literature Highlights here

FDA

Brenzavvy (bexagliflozin) approved by the FDA in adults with type 2 diabetes mellitus as an adjunct to diet and exercise

The South Asian Health Foundation (UK) guidelines for managing diabetes during Ramadan

Publication thumbnail: Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin versus Placebo and the DPP-4 Inhibitor Linagliptin versus Placebo in Young People with Type 2 Diabetes (DINAMO): a Multicentre, Randomised, Double-blind, Parallel Group, Phase 3 Trial

Efficacy and Safety of the SGLT2 Inhibitor Empagliflozin versus Placebo and the DPP-4 Inhibitor Linagliptin versus Placebo in Young People with Type 2 Diabetes (DINAMO): a Multicentre, Randomised, Double-blind, Parallel Group, Phase 3 Trial

Steering Committee